Direkt zum Inhalt
Merck
  • Coffee, tea, and caffeine consumption and prevention of late-life cognitive decline and dementia: a systematic review.

Coffee, tea, and caffeine consumption and prevention of late-life cognitive decline and dementia: a systematic review.

The journal of nutrition, health & aging (2015-03-04)
F Panza, V Solfrizzi, M R Barulli, C Bonfiglio, V Guerra, A Osella, D Seripa, C Sabbà, A Pilotto, G Logroscino
ZUSAMMENFASSUNG

A prolonged preclinical phase of more than two decades before the onset of dementia suggested that initial brain changes of Alzheimer's disease (AD) and the symptoms of advanced AD may represent a unique continuum. Given the very limited therapeutic value of drugs currently used in the treatment of AD and dementia, preventing or postponing the onset of AD and delaying or slowing its progression are becoming mandatory. Among possible reversible risk factors of dementia and AD, vascular, metabolic, and lifestyle-related factors were associated with the development of dementia and late-life cognitive disorders, opening new avenues for the prevention of these diseases. Among diet-associated factors, coffee is regularly consumed by millions of people around the world and owing to its caffeine content, it is the best known psychoactive stimulant resulting in heightened alertness and arousal and improvement of cognitive performance. Besides its short-term effect, some case-control and cross-sectional and longitudinal population-based studies evaluated the long-term effects on brain function and provided some evidence that coffee, tea, and caffeine consumption or higher plasma caffeine levels may be protective against cognitive impairment/decline and dementia. In particular, several cross-sectional and longitudinal population-based studies suggested a protective effect of coffee, tea, and caffeine use against late-life cognitive impairment/decline, although the association was not found in all cognitive domains investigated and there was a lack of a distinct dose-response association, with a stronger effect among women than men. The findings on the association of coffee, tea, and caffeine consumption or plasma caffeine levels with incident mild cognitive impairment and its progression to dementia were too limited to draw any conclusion. Furthermore, for dementia and AD prevention, some studies with baseline examination in midlife pointed to a lack of association, although other case-control and longitudinal population-based studies with briefer follow-up periods supported favourable effects of coffee, tea, and caffeine consumption against AD. Larger studies with longer follow-up periods should be encouraged, addressing other potential bias and confounding sources, so hopefully opening new ways for diet-related prevention of dementia and AD.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Supelco
Koffein, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Koffein, powder, ReagentPlus®
Sigma-Aldrich
Koffein, anhydrous, 99%, FCC, FG
USP
Koffein, United States Pharmacopeia (USP) Reference Standard
Supelco
Schmelzpunktstandard 235-237°C, analytical standard
Supelco
Coffein Schmelzpunktstandard, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
Koffein, certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland
USP
Koffein-Schmelzpunkt-Standard, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
Koffein, Sigma Reference Standard, vial of 250 mg
Sigma-Aldrich
Koffein, meets USP testing specifications, anhydrous
Supelco
Mettler Toledo Calibration Substance ME 18872, Caffeine, traceable to primary standards (LGC)
Sigma-Aldrich
Koffein, anhydrous, tested according to Ph. Eur.
Sigma-Aldrich
Koffein, BioXtra
Koffein für die Systemeignung, European Pharmacopoeia (EP) Reference Standard
Koffein, European Pharmacopoeia (EP) Reference Standard